Basilea Pharmaceutica AG
SIX:BSLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
KB Home
NYSE:KBH
|
US |
Basilea Pharmaceutica AG
Total Current Liabilities
Basilea Pharmaceutica AG
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Liabilities
CHf49.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Total Current Liabilities
$70.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Liabilities
$149.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
31%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Liabilities
CHf160.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Liabilities
CHf27m
|
CAGR 3-Years
27%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Current Liabilities
CHf3.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Total Current Liabilities?
Total Current Liabilities
49.2m
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Total Current Liabilities amounts to 49.2m CHF.
What is Basilea Pharmaceutica AG's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-3%
Over the last year, the Total Current Liabilities growth was 8%. The average annual Total Current Liabilities growth rates for Basilea Pharmaceutica AG have been -13% over the past three years , and -3% over the past ten years .
